Addiction Symposium

download Addiction Symposium
  • date post

    25-Nov-2014
  • Category

    Documents

  • view

    105
  • download

    1

Embed Size (px)

Transcript of Addiction Symposium

www.sobp.org/journalFriday Abstracts BIOL PSYCHIATRY 2010;67:1S-271S93SAbstracts from the annual meeting of the Society of Biological Psychiatry are not fully peer reviewed. Tey are not citeable and should not be included as reference sources.FRIDAY, MAY 21PLENARY SESSIONAddictionFriday, May 21, 2010 8:00 AM - 10:15 AMLocation: Grand Ballroom ABCChair: J. John Mann 324. The Genomics of AddictionDavid GoldmanNational Institute of Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MDDr. Goldman received his B.S. from Yale University in 1974. He received his M.D. degree in 1978 and completed residency training in psychiatry in 1979, both at the University of Texas Medical Branch. Dr. Goldman joined the NIAAA in 1979 and hasbeenChiefoftheLaboratoryofNeurogeneticssince1991.Throughouthis career, Dr. Goldman has focused on the identification of genetic factors responsible forinheriteddifferencesinbehavior,andhehasauthoredover300papers.His laboratory is currently exploring the genetics of alcoholism and related psychiatric diseases, and is well-known for his work identifying effects of functional genetic variants on intermediate phenotypes for complex behavioral diseases.325. Pharamacological and Genetic Modulation of Motivated Decision Making in Corticostriatal CircuitsMichael J. FrankBrown University, Providence, RIMichaelJ.FrankisAssistantProfessorofCognitive&LinguisticScience, Psychology,andPsychiatryintheBrownInstituteforBrainScienceatBrown University. He directs the Laboratory for Neural Computation. He received an undergraduate degree in Electrical Engineering at Queens University (Canada), followedbyaMastersdegreeinEngineeringwithbiomedicineoptionatthe University of Colorado at Boulder. He then received his PhD in Neuroscience andPsychologyattheUniversityofColoradoin2004,followedbyayearof postdoctoral work at the same institution. He then moved to the University of Arizonain2006until2009whenhemovedtoBrown.Dr.Frankisanactive member of multiple professional societies, including the Society for Neuroscience, the International Basal Ganglia Society, the Cognitive Neuroscience Society, and the Association for Psychological Science. He has authored over 40 publications, primarilyontheoreticalmodelsofbasalgangliaanddopaminefunctionin cognitionandtheirimplicationforParkinsonsDiseaseandrelateddisorders. This research utilizes computer models linking brain to behavior which are then testedandrefinedviaexperimentsusingpharmacologicalmanipulation,deep brainstimulation,electroencephalography,andgenetics.Awardsincludethe DG Marquis award for best paper published in Behavioral Neuroscience (2006). DrFrankisaContributingEditorfortheEuropeanJournalofNeuroscience, amemberofFacultyof1000Biology(TheoreticalNeurosciencesection), Consulting Editor for the Journal of Mathematical Psychology, guest editor of a special issue of Cognition, and ad-hoc reviewer for over 30 professional journals across domains of neuroscience, cognitive science, psychology, and computational neuroscience. He has also served as an Ad Hoc grant reviewer for the National Science Foundation, the Wellcome Trust (UK), the Neurological Foundation of New Zealand, the Netherlands Ogranisation for Scientific Research, and the UK Economic and Social Research Council.326. A Genomic Approach to the Treatment of AlcoholismCharles P. OBrienPsychiatry, University of Pennsylvania, Philadelphia, PACharles P. OBrien, a native of New Orleans, earned M.D. and Ph.D. degrees from Tulane University. He received residency training at Harvard, Tulane, University of London, and University of Pennsylvania in internal medicine, neurology and psychiatryandbecameboardcertifiedinbothneurologyandpsychiatry.As Chief of Psychiatry at the Philadelphia VA Medical Center, he was responsible for over 9,000 psychiatric patients. Despite this large clinical responsibility, he was able to establish and direct a clinical research program that has had a major impactonthetreatmentofaddictivedisorders.Hisresearchgrouphasbeen responsible for numerous discoveries described in over 500 publications that have elucidated basic information on the nature of addiction and improved the results of treatment for addictive disorders. His work involves discovery of CNS changes involved in relapse, new medications, behavioral treatments and instruments for measuring the severity of addictive disorders. He led the discovery of the effects of alcohol on the endogenous opioid system and demonstrated a completely new treatment for alcoholism. Many of his discoveries are now utilized in common practice for the treatment of addictive disorders throughout the world. His recent work has focused on a genetic subtype of alcoholism. A functional allele of the opiatereceptorpredictsresponsetoalcoholandcarriesanincreasedriskof bothalcoholismandopiateaddiction.OBrienwaselectedtotheInstituteof MedicineoftheNationalAcademyofSciencesin1991andhehasreceived numerous research and teaching awards as well as an honorary doctorate from the University of Bordeaux in 1994 and the Nathan B. Eddy award for research on addiction from the College on Problems of Drug Dependence in 2003.PRESIDENTIAL INVITED LECTUREFriday, May 21, 2010 10:50 AM - 11:50 AMLocation: Grand Ballroom ABCChair: J. John Mann 327. Addiction: Conict Between Brain CircuitsNora D. VolkowNational Institute on Drug Abuse, Bethesda, MDNoraD.Volkow,M.D.,becameDirectoroftheNationalInstituteonDrug Abuse (NIDA) at the National Institutes of Health in May 2003. NIDA supports most of the worlds research on the health aspects of drug abuse and addiction. Dr. Volkows work has been instrumental in demonstrating that drug addiction isadiseaseofthehumanbrain.Asaresearchpsychiatristandscientist,Dr. Volkowpioneeredtheuseofbrainimagingtoinvestigatethetoxiceffectsof drugsandtheiraddictiveproperties.Herstudieshavedocumentedchangesin the dopamine system affecting the actions of frontal brain regions involved with motivation, drive, and pleasure and the decline of brain dopamine function with age. She has also made important contributions to the neurobiology of obesity, ADHD, and the behavioral changes that occur with aging.Dr. Volkow was born in Mexico, attended the Modern American School, and earned her medical degree from the National University of Mexico in Mexico City, where she received the Premio Robins award for best medical student of her generation. Her www.sobp.org/journal94SBIOL PSYCHIATRY 2010;67:1S-271S Friday AbstractspsychiatricresidencywasatNewYorkUniversity,wheresheearnedtheLaughlin Fellowship Award as one of the 10 Outstanding Psychiatric Residentsin theUSA. Dr.VolkowspentmostofherprofessionalcareerattheDepartmentofEnergys BrookhavenNationalLaboratory(BNL)inUpton,NewYork,wheresheheld several leadership positions including Director of Nuclear Medicine, Chairman of the Medical Department, and Associate Director for Life Sciences. In addition, Dr. Volkow was a professor in the Department of Psychiatry and Associate Dean of the Medical School at the State University of New York (SUNY)-Stony Brook.Dr. Volkow has published more than 420 peer-reviewed articles and more than 60 book chapters and non-peer reviewed manuscripts, and has also edited three books on the use of neuroimaging in studying mental and addictive disorders. Duringherprofessionalcareer,Dr.Volkowhasbeentherecipientofmultiple awards, including her selection for membership in the Institute of Medicine in the National Academy of Sciences. She was recently named one of Time Magazines Top100PeopleWhoShapeourWorld,andwasincludedasoneofthe20 people to watch by Newsweek magazine in its Whos Next in 2007 feature. She was also named Innovator of the Year by U.S. News & World Report in 2000.SYMPOSIUMPrinciples of Methamphetamine Addiction: From Basic Neuroscience to Clinical PsychopharmacologyFriday, May 21, 2010 12:30 PM - 2:30 PMLocation: Oak Alley - 4th FloorChair: Jean Lud Cadet328. Molecular and Neurobiological Mechanisms of Methamphetamine AbuseJean Lud Cadet1,21Molecular Neuropsychiatry Branch, National Institute on Drug Abuse, NIH, DHHS, Baltimore, MD, 2Molecular Neuropsychiatry Branch, NIH NIDA Intramural Research Program, Baltimore, MDBackground: Methamphetamine use disorder is a neuropsychiatric syndrome which is characterized by periods of escalated drug intake and variable lengths of abstinence. Itsacutepsychologicaleffectsincludeeuphoriaandincreasedalertness.Useof chronic high methamphetamine doses is associated with irritability and psychosis. Wehavestudiedthemoleculareffectsofmethamphetamineinrodentmodelsin order to identify pathways that might be involved in methamphetamine abuseMethods: Sprague-Dawley rats were injected with methamphetamine either acutely or chronically. Animals were sacrificed at various time points and brain tissues were dissected and frozen until used in gene expression studies using microarray analyses or quantitative PCR. Other groups of rats were processed to measure status of histone modifications.Wealsoevaluatedtheeffectsofthedopaminereceptorantagonist, SCH23390, on methamphetamine-induced changes in gene expression.Results: Microarray analyses revealed that acute methamphetamine administration caused substantial changes in the expression of genes involved in signal transduction, transcriptionalregulation,apoptoticpathways.Wefoundthatstimulationof dopamine D1-like receptors is very important for the manifestation of these changes in gene expression. Acute administration of the drug induced significant dynamic epigeneticchangesinhistoneacetylationandmethylation.Incontrast,chronic administration of the drug caused changes in different classes of genes that participate in protective pathways and in structural plasticity, including BDNF.Conclusions: Our results are consistent with the notion that methamphetamine abuseisassociatedwithpleiotropicchangesinthebrain.Theelucidationof these processes will help in the development of better therapeutic approaches